PD-L1 expression and survival rates using TPS and CPS for nivolumab-treated head-and-neck cancer

T Ito, I Okamoto, K Tokashiki, H Sato… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: This study investigated the expression and survival rates of programmed
cell death ligand 1 using the tumor proportion score (TPS) and combined positive score …

Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab

I Okamoto, H Sato, K Tsukahara - Auris Nasus Larynx, 2020 - Elsevier
Objective Our facility measures programmed cell death ligand 1 (PD-L1) expression in all
patients before administering nivolumab. The aim of the present study is to clarify the …

Role of programmed death‐ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous …

Y Ueki, T Takahashi, H Ota, R Shodo… - Head & …, 2020 - Wiley Online Library
Background It was reported that treatment outcomes of the salvage chemotherapy (SCT)
following nivolumab are fairly good compared with those of nivolumab itself. However …

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with …

RL Ferris, G Blumenschein Jr, J Fayette, J Guigay… - Oral oncology, 2018 - Elsevier
Objectives We report 2-year results from CheckMate 141 to establish the long-term efficacy
and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with …

Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer

Y Sato, N Fukuda, YU Fujiwara, X Wang, T Urasaki… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …

Abstract CT021: tumor-associated immune cell PD-L1 expression and peripheral immune profiling: analyses from CheckMate 141

RL Ferris, G Blumenschein, K Harrington, J Fayette… - Cancer Research, 2017 - AACR
Introduction: In the phase 3 study CheckMate 141 (NCT02105636), patients with platinum-
refractory head and neck squamous cell carcinoma treated with nivolumab (NIVO) had …

[HTML][HTML] Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma

I Okamoto, K Tsukahara, H Sato - Scientific Reports, 2022 - nature.com
Nivolumab, an immune checkpoint inhibitor, is beneficial to patients with platinum-refractory
recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However …

[HTML][HTML] Prognostic markers in head and neck cancer patients treated with nivolumab

D Nishikawa, H Suzuki, Y Koide, S Beppu, S Kadowaki… - Cancers, 2018 - mdpi.com
To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1
antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated …

Five-year follow-up of patients with head and neck cancer treated with nivolumab and long-term responders for over two years

M Matsuo, R Yasumatsu, M Masuda, M Yamauchi… - in vivo, 2022 - iv.iiarjournals.org
Background/Aim: A long-term effect has been confirmed in clinical practice since the
introduction of nivolumab for treating various malignant tumors. A similar phenomenon is …

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab+ cisplatin/carboplatin+ fluorouracil) as first-line …

A Argiris, M Gillison, RL Ferris, K Harrington… - Annals of …, 2016 - annalsofoncology.org
Background Patients (pts) with recurrent/metastatic (R/M) SCCHN have a poor prognosis.
Addition of cetuximab to platinum and 5-FU (Extreme regimen) improved overall survival …